Pfizer v. Reddy: Drug Patents Under Fire

Generic firms are attacking drug patents--even before they expire--with increasingly clever legal strategies. And it looks like the FDA may be helping them do it.

Generic firms are attacking drug patents—even before they expire—with increasingly clever legal strategies. And it looks like the FDA may be helping them do it.

In a groundbreaking case with enormous implications for the drug industry and the patent extensions on which their valuations often...

More from Business Strategy

More from In Vivo